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Flavonoids are phytochemicals and belong to the polyphenols. A
wide variety of beneﬁcial factors has been attributed to their mode
of action. Some of their activities concerns the inhibition of in-
ﬂammatory pathways and the down regulation of genes involved
in chronic inﬂammatory disease states. These genes enhance the
inﬂammatory signaling pathways leading to expression of in-
ﬂammatory cytokines and chemokines. Flavonoids from fruits,
vegetable and tea compounds can block many proinﬂammatory
proteins and thus function as natural inhibitors of inﬂammation.
Instead of using nonsteroidal anti-inﬂammatory drugs natural in-
hibitors could possibly be used to suppress the intensity of the
inﬂammation in the chronically inﬂamed mucosa in patients with
chronic inﬂammatory bowel disease. Natural inhibitors like ﬂa-
vonoids are xenobiotics which are metabolized by the cytochrome
P-450 enzymes and conjugating protective enzymes. Flavonoids
can induce these protective enzymes by upregulation and thereby
could act as protective metabolic barrier within the intestinal
mucosa. The nutritional value of ﬂavonoids is probably related to
their anti-inﬂammatory activity and through this mechanism
responsible for prevention of neoplasia. The evidence for their
clinical efﬁcacy as essential compounds is still preliminary at best
and limited but suggestive.
© 2015 The Authors. Published by Elsevier Ltd on behalf of
European Society for Clinical Nutrition and Metabolism. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).oensch).
r Ltdonbehalfof EuropeanSociety forClinicalNutrition andMetabolism. This is
e (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Vitamins are essential for the human nutrition. They cannot be synthesized in the body, they need
to be taken up from exogenous sources in our nutrition and are essential for the health and the function
of our body. Flavonoids are similar in that they cannot be synthesized, they are foreign compounds and
are contained in our nutrition, but are they really essential for the human health? Could these phy-
tochemicals play a role comparable to that of vitamins? To ﬁnd out about this we have to explore their
fate when they interact with the biology of the organism. Plant derived phytochemicals play an
important role as protective factors against free radicals, reactive oxygen species and toxic chemical
compounds. The concept of their role as natural inhibitors of inﬂammation has evolved recently [1,2]
and their metabolism was clariﬁed [3] .
Flavonoids belong to the polyphenols and are widely distributed within the plant kingdom and are
mainly contained in fruits, vegetables and teas [4]. There are more than 4000 ﬂavonoid species and
there are 6 major groups according to their chemical structure: Flavones, ﬂavonols, ﬂavanols, ﬂava-
nones, anthocyanidins and isoﬂavonoids [5].
2. Physiology
The uptake and the absorption takes place in the small intestinal mucosa but only small amounts
enter the central compartment of the body from where they reach the liver and the kidney. Phase 1
metabolism by cytochrome P-450 enzymes and phase 2 metabolism by conjugating enzymes are
performed in the liver and the gut and the water-soluble products are excreted by the kidney and into
the bile [3]. Themucosa is exposed to amuch higher concentration than the other tissues and therefore
here the biological activity is concentrated. A great fraction remains within the lumen of the gut and
reaches the colon where the ﬂavonoids are metabolized by the microbiota to small breakdown
products among them butyrate and acetate which are the metabolic fuel of the mucosa.
3. Function
Flavonoids use the same xenobiotic metabolizing enzyme systemwhich is used for the distribution
and disposition of drugs but do they exercise drug related effects?
There is a wealth of clinical and laboratory studies and data that suggest that ﬂavonoids have
beneﬁcial effects in a wide variety of clinical ﬁelds such as cardiovascular disorders [6], neurology,
urology, immunology and last but not least gastroenterology (Table 1). It is difﬁcult to ﬁnd a common
functional denominator that can explain all these ﬁndings. The most convincing factor which could
explain the beneﬁcial ﬁndings is that ﬂavonoids act best in preventing medicine. Flavonoids need to be
given before the pathophysiological event occurs. That could mean that a protective wall should be
induced before the noxious factor comes into play. The mechanism which is used to build up the
Table 1
Beneﬁcial effects of ﬂavonoids in disease states [7].
Anticarcinogenic activities Colorectal cancer, cancer of liver, esophagus, breast, non-Hodgkin lymphoma [17]
Cardiovascular improvement Rate of stroke reduced, lower blood pressure [18]
Metabolic control improved Diabetes mellitus improved [19]
Neuroprotection Cognitive enhancement [20]
Antisecretory action Diarrheal disease treatment [21]
Restoration of intestinal microﬂora Improvement of microbiota [8]
Prevention of metabolic disease Treatment of obesity [22]
Intestinal barrier protection Prevention of colitis [23]
H.P. Hoensch, R. Oertel / Clinical Nutrition Experimental 3 (2015) 8e1410protective enzymes is by enzyme induction. This involves activation of the related genes via cytosolic
transcription factors using the xenobiotic response element which is transferred into the nucleus of the
exposed cells [7]. Flavonoids can bind to the Toll like receptors [8] of the plasma membrane and thus
initiate the process of enzyme induction. Many of the protective enzymes have antioxidative functions
and can trap oxygen radicals and other free radicals.4. Anti-inﬂammatory activities by natural inhibitors
Inﬂammatory states are common in clinical medicine [1] and it is now believed that chronic
inﬂammation is the base for many degenerative disorders such as cardiovascular diseases, athero-
sclerosis, rheumatic disorders and osteoarthritis. In the past infectious agents were held responsible for
many chronic ailments such as chronic inﬂammatory bowel disease but it now becomes clear that a
persistently activated inﬂammatory cascade is the cause for many of these disorders [9]. The signaling
pathways for inﬂammation are chronically activated and the inﬂammatory genes are overexpressed
(Fig. 1). The components of this pathway have been delineated and could serve as targets for therapy
with drugs and biological agents. Speciﬁc immunologic proteins such as cytokines and chemokines
were discovered and their role in chronic inﬂammation has been clariﬁed [10]. Flavonoids such as teaFig. 1. Blockage of inﬂammatory signal pathway by tea ﬂavonoids in patients with chronic inﬂammatory bowel disease.
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and their efﬁcacy in clinical models is being tested. Figures 2 and 3 illustrate the inhibitory action of
ﬂavonoids at the level of cytokine and chemokine production [11].
5. Natural inducers
Flavonoids can induce protective enzymes such as certain cytochrome P-450 enzymes (CYP 3A4)
and conjugating enzymes such as glucuronosyl transferases and glutathione transferases. These en-
zymes metabolize carcinogenic environmental compounds and thereby detoxify these chemicals [5].
By way of natural induction the intestinal mucosa builds up a metabolic barrier which prevents the
intrusion of noxious compounds into the body. A diet which lacks ﬂavonoids is devoid of this capacity
and cannot maintain this metabolic barrier. The clinical consequences of a failing metabolic barrier are
unfavorable genetic mutation with development of hyperplasia, aberrant crypt foci and dysplasia as
well as adenomas and carcinomas in the intestinal mucosa. Some years agowe have published, that an
artiﬁcial enteric diet which lacks natural inducers depresses the xenobiotic P-450 enzyme system of
the small intestinal mucosa in patients [12]. Recently we found that the conjugating phase 2 enzymes
of the colonic mucosa are diminished in patients with colon cancer compared to adenoma patients
[13]. This could mean that there is a progressive loss of protective enzymes activities during the
neoplastic development. Flavonoids might play a role as natural inducers and thus prevent neoplasia.
However this notion is still hypothetical since some P-450 enzymes can toxify foreign compounds into
carcinogenic products.
6. Microbiota
Flavonoids inﬂuence the composition of the microbial ﬂora within the colon lumen both quanti-
tatively and qualitatively. Thereby they act as prebiotics and support the growth of biﬁdum and lac-
tobacilli bacteria [14]. Lack of certain phytochemicals in the diet could lead to an inﬂammatory status
and ﬂavonoids could stimulate the anti-inﬂammatory aryl hydrocarbon Ah receptor [15].
7. Challenges and opportunities
Our nutrition seems to promote an inﬂammatory status in the body especially in the gut and in the
liver. Inﬂammatory genes are upregulated, cytokines and chemokines are overexpressed. The balance
between protective and toxifying enzymes is disturbed especially at their portal of entry in the mucosa
of the gut. There is an increase of dietary toxins due to the modern modes of food processing and
production. At the same time the protective factors are reduced due to a lack of plant derived poly-
phenols such as ﬂavonoids. These compounds could provide a metabolic barrier and could act much
like anti-inﬂammatory drugs such as nonsteroidal anti-inﬂammatory drugs (NSAID's) but without
their unwanted side effects [1]. There is a chance that dietary supplements on ﬂavonoid bases could
replace drugs in chronic inﬂammatory bowel diseases. However, their safety, efﬁcacy, tolerability and
their pharmacology need to be examined in valid clinical studies. Flavonoid sources as nutritionalTable 2
Anti-inﬂammatory efﬁcacy of ﬂavonoids from green tea (EGCG) and from chamomile (Apigenin).
EGCG Apigenin
Cytokine MCP-1 YY COX-2 Y
RANTES YY NO Y
MIP-1 YY NF-kB Y
JAK Y
Cellular Targets T-cells Y Monocytes Y
APC-cells Y Makrophages Y
Neutrophiles Y
MIP: makrophage inhibitory protein MCP: monocytes chemoattractant protein RANTES: chemokine
CCL-5 APC: adenomatosis polyposis coli cells Y inhibition.
Fig. 2. Stimulation of cancer cells by cytokine IL-2 and its inhibition by ﬂavanols.
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recurrence of neoplasia in patients with colorectal cancer [16]. These ﬂavonoid capsules consist of a
ﬂavonoid mixture [7] (mainly apigenin-10 mg- and epigallocatechin gallate-10 mg per capsule),Fig. 3. Inhibition of chemotaxis by ﬂavanols.
H.P. Hoensch, R. Oertel / Clinical Nutrition Experimental 3 (2015) 8e14 13400 mg inulin and a vitamin mixture (110 mg vitamin C, 2.6 mg vitamin B 6, 220 mg folic acid and 4 mg
vitamin B 12).
The nutritional value of ﬂavonoids in vivo and in vitro is quite convincing but it is still unclear
whether they are essential and which speciﬁc species are most efﬁcacious for which clinical indi-
cation. For the clinical application the evidence is limited but suggestive. To prove causality clinical
intervention studies with deﬁned amounts of ﬂavonoids and valid clinical endpoints and outcomes
are required. Furthermore it would be interesting to look at the pathophysiology of animals on
ﬂavonoid deﬁcient diet. However, so far no ﬂavonoid deﬁciency disease has been identiﬁed [4].
Patients on Flavonoid-depleted nutrition like the one on oral elemental and total parenteral nutrition
could suffer from chronic persistent inﬂammation [12]. They could be a model for a ﬂavonoid deﬁ-
ciency syndrome.
Conﬂict of interest
Harald Hoensch holds a patent for a ﬂavonoid combination.
Reinhard Oertel: None.
References
[1] Conti P, Varvara G, Murmura G, Tete S, Sabatino G, Saggini A, et al. Comparison of beneﬁcial actions of non-steroidal anti-
inﬂammatory drugs to ﬂavonoids. J Biol Regul Homeost Agents 2013 Jan-Mar;27(1):1e7. PMID: 23489682.
[2] Langhorst J, Varnhagen I, Schneider SB, Albrecht U, Rueffer A, Stange R, et al. Randomised clinical trial: an herbal prep-
aration of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis-a
double-blind, double-dummy study. Aliment Pharmacol Ther 2013;38(5):490e500.
[3] Moon YJ, Wang X, Morris ME. Dietary ﬂavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 2006
Mar;20(2):187e210. Epub 2005 Nov 11. PMID: 16289744.
[4] Birt DF, Jeffery E. Flavonoids Adv Nutr 2013 Sep 1;4(5):576e7. http://dx.doi.org/10.3945/an.113.004465. PMID: 24038263.
[5] Hoensch HP, Oertel R. Emerging role of bioﬂavonoids in gastroenterology: especially their effects on intestinal neoplasia.
World J Gastrointest Oncol 2011;3(5):71e4.
[6] Sies H, Hollman PC, Grune T, Stahl W, Biesalski HK, Williamson G. Protection by ﬂavanol-rich foods against vascular
dysfunction and oxidative damage: 27th Hohenheim Consensus Conference. Adv Nutr 2012 Mar 1;3(2):217e21. http://dx.
doi.org/10.3945/an.111.001578. PMID: 22516731.
[7] Hoensch HP, Kirch W. Potential role of ﬂavonoids in the prevention of intestinal neoplasia: a review of their mode of action
and their clinical perspectives. Int J Gastrointest Cancer 2005;35(3):187e95. Review. PMID: 16110120.
[8] Magrone T, Jirillo E. The interplay between the gut immune system and microbiota in health and disease: nutraceutical
intervention for restoring intestinal homeostasis. Curr Pharm Des 2013;19(7):1329e42. PMID: 23151182.
[9] Miyazaki H, Takabe K, Yeudall WA. Chemokines, chemokine receptors and the gastrointestinal system. World J Gastro-
enterol 2013 May 21;19(19):2847e63. http://dx.doi.org/10.3748/wjg.v19.i19.2847. PMID: 23704819.
[10] O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeﬁciency, and cancer N. Engl J Med 2013 Jan 10;
368(2):161e70. http://dx.doi.org/10.1056/NEJMra1202117. PMID: 23301733.
[11] Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inﬂammation. N Engl J Med 2006 Feb
9;354(6):610e21. PMID: 16467548.
[12] Hoensch HP, Steinhardt HJ, Weiss G, Haug D, Maier A, Malchow H. Effects of semisynthetic diets on xenobiotic metabo-
lizing enzyme activity and morphology of small intestinal mucosa in humans. Gastroenterology 1984 Jun;86(6):1519e30.
PMID: 6425105.
[13] Hoensch HP, Roelofs HM, Edler L, Kirch W, Peters WH. Disparities of conjugating protective enzyme activities in the colon
of patients with adenomas and carcinomas. World J Gastroenterol 2013 Sep 28;19(36):6020e5. http://dx.doi.org/10.3748/
wjg.v19.i36.6020. PMID: 24106402.
[14] Axling U, Olsson C, Xu J, Fernandez C, Larsson S, Str€om K, et al. Green tea powder and Lactobacillus plantarum affect gut
microbiota, lipid metabolism and inﬂammation in high-fat fed C57BL/6J mice. Nutr Metab (Lond) 2012 Nov 26;9(1):105.
http://dx.doi.org/10.1186/1743-7075-9-105. PMID: 23181558.
[15] Tilg H, Koch R, Moschen AR. Proinﬂammatory wheat attacks on the intestine: alpha-amylase trypsin inhibitors as new
players. Gastroenterology 2013 Jun;144(7):1561e3. http://dx.doi.org/10.1053/j.gastro.2013.04.035. discussion 1563-4.
Epub 2013 Apr 25. PMID: 23623873.
[16] Hoensch H, Groh B, Edler L, Kirch W. Prospective cohort comparison of ﬂavonoid treatment in patients with resected
colorectal cancer to prevent recurrence. World J Gastroenterol 2008;14(14):2187e93.
[17] Yang Y, Zhang D, Feng N, Chen G, Liu J, Chen G, et al. Increased intake of vegetables, but not fruit, reduces risk for he-
patocellular carcinoma: a meta-analysis. Gastroenterology 2014 Nov;147(5):1031e42. http://dx.doi.org/10.1053/j.gastro.
2014.08.005. Epub 2014 Aug 13. Review. PMID: 25127680.
[18] Hollman PC, Cassidy A, Comte B, Heinonen M, Richelle M, Richling E, et al. The biological relevance of direct antioxidant
effects of polyphenols for cardiovascular health in humans is not established. J Nutr 2011 May;141(5):989Se1009S. http://
dx.doi.org/10.3945/jn.110.131490. Epub 2011 Mar 30. Review.
[19] Scalbert A, Zamora-Ros R. Bridging evidence from observational and intervention studies to identify ﬂavonoids most
protective for human health. Am J Clin Nutr 2015 May;101(5):897e8. pii: ajcn110205. [Epub ahead of print] No abstract
available. PMID: 25832341.
H.P. Hoensch, R. Oertel / Clinical Nutrition Experimental 3 (2015) 8e1414[20] Macready AL, Kennedy OB, Ellis JA, Williams CM, Spencer JP, Butler LT. Flavonoids and cognitive function: a review of
human randomized controlled trial studies and recommendations for future studies. Genes Nutr 2009 Dec;4(4):227e42.
http://dx.doi.org/10.1007/s12263-009-0135-4. Epub 2009 Aug 13. PMID: 19680703.
[21] Thiagarajah JR, Ko EA, Tradtrantip L, Donowitz M, Verkman AS. Discovery and development of antisecretory drugs for
treating diarrheal diseases. Clin Gastroenterol Hepatol 2014 Feb;12(2):204e9. http://dx.doi.org/10.1016/j.cgh.2013.12.001.
Epub 2013 Dec 4. Review. PMID: 24316107.
[22] Chuang CC, McIntosh MK. Potential mechanisms by which polyphenol-rich grapes prevent obesity-mediated inﬂamma-
tion and metabolic diseases. Annu Rev Nutr 2011 Aug 21;31:155e76. http://dx.doi.org/10.1146/annurev-nutr-072610-5149.
Review. PMID: 21548775.
[23] T1 Azuma, Shigeshiro M, Kodama M, Tanabe S. Suzuki T.Supplemental naringenin prevents intestinal barrier defects and
inﬂammation in colitic mice. J Nutr 2013 Jun;143(6):827e34. http://dx.doi.org/10.3945/jn.113.174508. Epub 2013 Apr 17.
